Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Moderna (NASDAQ:MRNA) and its peers.
Nvidia is rated a Buy, reported its Q2 print and first full-year outlook, and Vera Rubin is propping up the Q3 outlook. Read ...
CMB.TECH shows improved earnings quality as core shipping EBITDA rises despite reduced ship sales. Click here to read an ...
Tomer Weingarten, SentinelOne CEO, joins 'The Exchange' to discuss the company's quarterly earnings results, what's happening ...
Nvidia's latest quarterly results once again blew past Wall Street's expectations as revenue for the computer chip company's ...
Lululemon (LULU) stock jumped 4.4% Friday as institutional investors disclosed new positions ahead of Q2 earnings, despite ...
Walmart Inc. announced its financial results for the second quarter of fiscal year 2027 and retail analysts were not ...
There were several common purchases among hedge funds in Q2.
CNBC's Kristina Partsinevelos, Deepwater's Gene Munster, and Benchmark's Cody Acree join 'Closing Bell Overtime' to talk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results